SCRIP
CITELINE COMMERCIAL

21 May 2023 | **News**

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: US FTC takes action on Amgen's Horizon deal; Hassan and Jimenez share their CEO experiences; Novartis lays out Cosentyx plans; generally strong fiscal year for Japan's pharma firms; and new Tagrisso data lift AstraZeneca.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip*'s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 19 May 2023, including: US FTC takes action on *Amgen, Inc.*'s *Horizon Therapeutics plc* deal; Hassan and Jimenez share their CEO experiences; *Novartis AG* lays out Cosentyx plans; generally strong fiscal year for Japan's pharma firms; and new Tagrisso data lift *AstraZeneca PLC*.

This and all our other podcasts are available on the Pharma Intelligence channel on *Apple Podcasts*, *Google Podcasts*, *SoundCloud*, *TuneIn* and *Spotify Podcasts*, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "*FTC's Challenge Of Amgen/Horizon Merger Seeks To Fight Pharma Rebating Practices*" - Scrip, 16 May, 2023.)

(Also see "*The Benefit Of Hindsight: Strategic Leadership Lessons From Pharma's Past CEOs*" - Scrip, 16 May, 2023.)

(Also see "*Novartis Committed To Carving Out More Indications For Cosentyx*" - Scrip, 12 May, 2023.)

© Citeline 2024. All rights reserved.

SCRIP
CITELINE COMMERCIAL

(Also see "*Japan Results Round-Up: Astellas, Daiichi Sankyo, Chugai Solid, Shionogi Hits New Heights*" - Scrip, 16 May, 2023.)

(Also see "*AstraZeneca Lifted By Tagrisso Combo Lung Cancer Data*" - Scrip, 17 May, 2023.)

Click here to explore this interactive content online

© Citeline 2024. All rights reserved.